Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2024-04-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
独立董事2023年度述职报告（庞金伟）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" for Chongqing Boteng Pharmaceutical Technology Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various company matters, communication with internal audit and external accounting firms, and efforts to protect investor rights during the year 2023. The content focuses on the independent director's duties, opinions, and oversight rather than financial results or operational data. It is a formal report on the director's management and governance role rather than a financial report or announcement. This fits best under the category of Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2024-04-26 Chinese
关于举行2023年度暨2024年第一季度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is a short announcement (1015 characters) about the scheduling of an online performance explanation meeting (业绩说明会) for the 2023 annual and 2024 first quarter results. It references that the full 2023 annual report and 2024 Q1 report have already been disclosed on April 27, 2024, and invites investors to participate in a Q&A session on April 30, 2024. There is no actual financial data or detailed report content in this document, only an announcement of the meeting and instructions for participation. According to the 'Menu vs Meal' rule, this is not the report itself but an announcement related to the report and investor communication. Therefore, the appropriate classification is Investor Presentation (IP), as it is a detailed presentation event for investors focusing on financials and strategy, or possibly a Regulatory Filing (RNS) if it were a general announcement. However, since it is specifically about an earnings explanation meeting, the best fit is Investor Presentation (IP). Confidence is high given the clear description and nature of the document.
2024-04-26 Chinese
监事会关于终止实施2021年限制性股票激励计划暨回购注销相关限制性股票的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the termination of the 2021 restricted stock incentive plan and related repurchase and cancellation of restricted stock. It references relevant laws and regulations and concludes that the termination and repurchase comply with regulations and do not materially affect the company's financial condition. The document is short (612 characters) and is a formal opinion or certification by the supervisory board rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data. It is not an announcement of voting results or a proxy solicitation but a regulatory compliance opinion related to stock incentive plans and repurchase. Given the nature and length, it fits best under Regulatory Filings (RNS) as a compliance document and supervisory board opinion rather than a full report or announcement.
2024-04-26 Chinese
董事会对独董独立性评估的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board regarding the independence evaluation of independent directors, referencing regulatory guidelines and internal company rules. It does not contain financial data, audit results, or management changes but focuses on governance compliance related to board members' independence. The content aligns with governance-related disclosures rather than financial reports or announcements. Given the nature of the document, it fits best under Governance Information (CGR). The document length is short and specific, not an announcement or certification, so it is not RNS or RPA.
2024-04-26 Chinese
中信证券股份有限公司关于重庆博腾制药科技股份有限公司2023年度募集资金存放与使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度募集资金存放与使用情况的专项核查报告" which translates to a "Special Verification Report on the Deposit and Use of Raised Funds for 2023". It is issued by a sponsoring institution (中信证券股份有限公司) for 重庆博腾制药科技股份有限公司. The content details the amount of funds raised, their deposit, usage, changes in investment projects, and compliance with regulatory requirements. It includes tables showing the use of raised funds and changes in projects, as well as an auditor's opinion on the raised funds usage. This type of document is a specialized audit or verification report focusing on the management and use of raised capital, not a full annual report or interim financial report. It is not a simple announcement or certification but a detailed audit-related report on fundraising usage. Therefore, it fits best under the category Audit Report / Information (AR). FY 2023
2024-04-26 Chinese
募集资金年度存放与使用情况鉴证报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual storage and usage of raised funds by Chongqing Boteng Pharmaceutical Technology Co., Ltd. It includes an auditor's verification report, management's special report on the use of raised funds for the year 2023, detailed tables on fund usage, changes in investment projects, and compliance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document is over 7,000 characters and contains substantive financial data and analysis related to the company's fundraising and capital usage. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report, nor a full annual report or audit report, but a specialized report on fundraising usage and verification, fitting best under CAP.
2024-04-26 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.